SAN DIEGO, Oct. 08, 2023 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Morphic Holding, Inc. (NASDAQ: MORF) focused on whether Morphic and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.
If you have information that could assist in this investigation or if you are a Morphic investor who suffered a loss and would like to learn more, you can provide your information here:
https://www.rgrdlaw.com/cases-morphic-holding-inc-investigation-morf.html
You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com.
THE COMPANY: Morphic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
THE REVELATION: On September 22, 2023, Morphic released abstract data from its EMERALD-1 Phase 2a trial for its MORF-057 drug, revealing that “endoscopic improvement was achieved in 25.7% of patients.” Following this news, the price of Morphic stock declined.
ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: Robbins Geller is one of the world’s leading complex class action firms representing plaintiffs in securities fraud cases. The Firm is ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report for recovering more than $1.75 billion for investors in 2022 – the third year in a row Robbins Geller tops the list. And in those three years alone, Robbins Geller recovered nearly $5.3 billion for investors, more than double the amount recovered by any other plaintiffs’ firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Contact:
Robbins Geller Rudman & Dowd LLP
655 W. Broadway, Suite 1900, San Diego, CA 92101
J.C. Sanchez, 800-449-4900
jsanchez@rgrdlaw.com
- Thermosome Receives U.S. Orphan Drug Designation for Lead Compound THE001, Expands Patent Estate - May 12, 2025
- Lead Service Line Replacement Cost Calculator (LSLRCC) Federal Trademark and Copyright Applications Filed by Environmental & Public Health International - May 12, 2025
- PageUp Unifies Brands to Strengthen Market Leadership and Enhance Customer Experience - May 12, 2025
